Physicians' Academy for Cardiovascular Education

Diabetes

Recently added learning

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD
5 Things a cardiologist needs to know about GLP-1 RA

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD - Online CME
5 Things a cardiologist needs to know about GLP-1 RA

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD - Online CME

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD - Online CME

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD
5 Things a cardiologist needs to know about GLP-1RA

Which patients to consider for GLP-1RA?

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD - Online CME

The role of GLP-1 receptor agonists in CVD prevention

10' education - Nov. 6, 2020 - Prof. Kamlesh Khunti, MD - Online CME

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

Introduction: Expanding focus for cardiologists - The patient with diabetes and cardiovascular outcomes

10' education - Oct. 3, 2020 - Prof. Ulf Landmesser, MD

Changing paradigm in prediabetes and CVD: Potential for new concepts and new tools

10' education - Sep. 28, 2020 - Prof. John E Deanfield, MD - Online CME

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD

More insight into daily clinical practice and more collaboration needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD

Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

Barriers to implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM

5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg

DAPT strategy results in favorable net clinical benefit in CAD patients with diabetes and prior PCI

3' education - Sep. 1, 2019 - Prof. Deepak Bhatt

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD - Online CME

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD - Online CME

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada

Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR

3' education - Apr. 17, 2019

Reduction in renal outcomes with selective endothelin receptor antagonist in patients with diabetic kidney disease

3' education - Apr. 17, 2019 - Melbourne, Australia

Endothelin receptor antagonist gives renoprotection in selected patients with T2DM and CKD

3' education - Apr. 15, 2019 - Melbourne, Australia

Hopeful results with SGLT2 inhibitor in patients with T2DM and chronic kidney disease

3' education - Apr. 15, 2019 - Melbourne, Australia

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Diabetes & CVD: Time for a multifactorial approach

10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD London, United Kingdom - Online CME

Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK - Online CME

Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Lina Badimon, MD Barcelona, Spain - Online CME

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden - Online CME

SGLT2 inhibitor treatment may now be considered in broader T2DM population

3' education - Nov. 11, 2018 - Steve Wiviott, MD - Boston, MA, VS.

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands

In a primary prevention setting of diabetes patients, aspirin did not give overall benefit

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

Weight loss agent showed CV safety in high-risk patients with overweight or obesity

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No CV benefit with omega-3 fatty acid supplements

3' education - Aug. 26, 2018

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK - Online CME

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK - Online CME

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France - Online CME

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland - Online CME

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands - Online CME

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

What are the key mechanisms of CV benefit of novel diabetes drugs?

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar - Online CME

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser - Online CME

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

Key classes of antidiabetic drugs – How do they work?

10' education - Feb. 14, 2018 - Prof Cliff Bailey - Birmingham, UK - Online CME

Diabetes cardiovascular outcome trials

10' education - Feb. 14, 2018 - Prof. Lawrence Leiter, MD - Toronto, ON, Canada - Online CME

HbA1c in CVD

10' education - Feb. 14, 2018 - Prof Naveed Sattar, MD - University of Glasgow, United Kingdom - Online CME

Natural history of DM: Focus on micro- and macrovascular complications

10' education - Feb. 13, 2018 - Prof. Kausik Ray, Imperial College London, UK - Online CME

Diabetic dyslipidemia and residual risk in the era of LDL control

10' education - Jan. 25, 2018 - Boston, MA, USA - Dr. Aruna Pradhan - Brigham & Women's Hospital, Boston, USA

Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

10' education - Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

New therapeutic options can make a difference for diabetic patients with high CV risk

3' education - Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK

Cardiovascular protection in type 2 diabetes

5' education - Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden

Insights from the first trials in epigenetics in human: What is the way forward?

10' education - Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017 - Online CME

Brief update on the LEADER cardiovascular outcomes trial

10' education - Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK

Management of CV Risk & T2DM: Implications of novel outcome trials

10' education - Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017 - Online CME

The Clinical Unmet need in the patient with Diabetes and ACS

10' education - Aug. 26, 2017 - Barcelona, Spain - Kausik Ray, MD Imperial College London United Kingdom - PACE-CME symposium held at ESC 2017 - Online CME

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

UK: Clinical Dialogues: Lipids & Diabetes 2017

3' education - July 7, 2017 - Stratford Upon Avon, United Kingdom - Prof Peter Sever

How incretin therapy changes diabetes and prediabetes management

3' education - May 22, 2017

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

3' education - Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

Modifying CV risk by managing diabetes

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

Update on SGLT2 inhibition in T2DM: A closer look at EMPA-REG OUTCOME

Lecture - July 31, 2016 - Asian Interchange on Diabetes - David Fitchett, MD – University of Toronto, Canada

CV Protection in the EMPA-REG OUTCOME Trial: A ‘Thrifty Substrate’ Hypothesis

Lecture - July 31, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research

Update on DPP4 inhibition in T2DM: Implications from recent and ongoing trials

Lecture - July 31, 2016 - Asian Interchange on Diabetes meeting - Richard E. Pratley, MD – Florida Hospital Diabetes Institute, Orlando, Fl, USA

Understanding Diabetic Kidney Disease: What are the best options for clinical management?

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Per-Henrik Groop, MD – University of Helsinki, Helsinki, Finland

Diabetes and Cardiovascular Disease: A review of new outcome data impacting practice

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - David Fitchett, MD – University of Toronto, Canada

Need for ongoing clinical innovation in management of T2DM: A closer look at the development process of new entities

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research

Management of hyperglycemia in type 2 diabetes: Update on novel trends and developments

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Richard E. Pratley, MD – Florida Hospital Diabetes Institute, Orlando, FL, USA

Diabetes in Asia: What is different from the west?

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Chaicharn Deerochanawong, MD – Rajavithi Hospital College of Medicine, Bangkok, Thailand

HF & Diabetes: SGLT2 inhibition a paradigm shift?

10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

Challenging cardiovascular risk in diabetes: ready for a new approach?

10' education - Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

10' education - Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

10' education - Aug. 28, 2016 - ESC 2016, Rome - Kausik Ray, MD – Imperial College London, United Kingdom - Recorded at PACE-CME symposium at ESC 2016
##FULL_TITLE##

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##FULL_TITLE##

A changing treatment paradigm in diabetes

3' education - July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)

SGLT2 inhibition in diabetic kidney disease

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##FULL_TITLE##

Exciting times in diabetes treatment: new drug class moves beyond glucose reduction

3' education - Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Current treatment of Diabetes in Heart Failure

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands

New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA
##FULL_TITLE##

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

3' education - May 10, 2016 - David Fitchett, MD, University of Toronto, Canad

CV protection by SGLT2 inhibition: Potential mechanisms for benefit

3' education - May 10, 2016 - Kuala Lumpur, Malaysia - Prof Hiddo Lambers Heerspink, Groningen, The Netherlands
##FULL_TITLE##

Review of cardiovascular safety of DPP4 inhibitors

3' education - May 6, 2016 - Dubai, UAE - Dr Sanjay Rajagopalan, MD, Maryland
##FULL_TITLE##

Stroke reduction with PPAR-Y antagonist pioglitazone

3' education - May 6, 2016 - Dubai, UAE - Dr Robert J Chilton
##FULL_TITLE##

Diabetic dyslipidaemia and residual risk in the era of LDL control

10' education - Mar. 21, 2016 - Boston, MA, USA - Aruna Pradhan
##FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##FULL_TITLE##

Recent advances in lowering CV risk with antidiabetic agents

3' education - Feb. 12, 2016 - Boston, MA, USA - Prof Stephen Wiviott
##FULL_TITLE##

CV outcomes with medicines to control glycemia: highlights from recently completed trials

3' education - Feb. 2, 2016 - VBWG, Orlando - Darren K. McGuire, MD

The mechanism of SGLT2 inhibition in glucose control

Nov. 24, 2015
##FULL_TITLE##

Antidiabetic therapy reduces CV mortality and HF outcomes in high-risk patients

3' education - Nov. 10, 2015 - AHA 2015, Orlando, FL, USA - Prof. Silvio Inzucchi
##FULL_TITLE##

SGLT2 inhibitor outcome trials: Future opportunities

10' education - Sep. 27, 2015 - London - Dr David Fitchet, Toronto, Canada
##FULL_TITLE##

SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

10' education - Sep. 29, 2015
##FULL_TITLE##

What is the story about Diabetes & CVD: Rationale for a multifactorial approach

10' education - Sep. 29, 2015
##FULL_TITLE##

Diabetes & Cardiovascular Disease:The risk factor to be challenged

10' education - Sep. 27, 2015
##FULL_TITLE##

Cardiovascular effects of glucose lowering: Safety vs Efficacy

3' education - Dec. 12, 2014 - AHA, Chicago VBWG - Dr Silvio E Inzucchi
##FULL_TITLE##

What do novel diabetes drugs add to CV risk reduction?

3' education - Oct. 19, 2014 - Snapshot 2014 - Dr Naveed Sattar
##FULL_TITLE##

Diabetes and reducing CVD: Are novel interventions living up to their promise?

10' education - Sep. 5, 2014 - Snapshot 2014 - Naveed Sattar MD, Glasgow
##FULL_TITLE##

Neurological complications in diabetes

3' education - Apr. 23, 2014 - CDMC Almaty - Boris Mankovsky
##FULL_TITLE##

Impact of new diabetes drugs on cardiovascular outcomes

3' education - Apr. 18, 2014 - VBWG - ACC 2014 - Deepak L. Bhatt
##FULL_TITLE##

Diabetes, glycemic control & vascular prevention

3' education - June 16, 2013 - CDMC Hanoi - Prof John Betteridge
##FULL_TITLE##

HPS2-THRIVE and the future of clinical endpoint trials

3' education - May 12, 2013 - CDMC hanoi - Prof D John Betteridge

CV disease & diabetes in Asia

10' education - Apr. 15, 2013
##FULL_TITLE##

Effects of GLP-1 Analogs on Cardiovascular Health

3' education - Jan. 10, 2013 - LA, AHA 2012 - Dr. Richard Shannon
##FULL_TITLE##

Dual PPAR agonists in CV risk & diabetes

3' education - Dec. 11, 2012
##FULL_TITLE##

Achieving optimal glycemic control: What are the current options in management?

3' education - Dec. 7, 2011
##FULL_TITLE##

Diabetes & CV Risk: routine practice versus guidelines

3' education - July 29, 2011
##FULL_TITLE##

Priorities in the management of type 2 diabetes

3' education - July 29, 2011
##FULL_TITLE##

Management of diabetes

3' education - July 26, 2011
##FULL_TITLE##

HbA1c: targets & recommendations

3' education - July 25, 2011
##FULL_TITLE##

Optimal blood pressure management

3' education - July 22, 2011
##FULL_TITLE##

Diabetes & vascular risk:

3' education - June 16, 2011
##FULL_TITLE##

TZD's and CV risk-benefit

3' education - Apr. 7, 2011
##FULL_TITLE##

TZD's and CV risk-benefit

3' education - Apr. 7, 2011
##FULL_TITLE##

TZD's and CV risk-benefit

3' education - Apr. 7, 2011
##FULL_TITLE##

Diabetes & CV disease

3' education - Oct. 3, 2009
##FULL_TITLE##

CV risk in diabetes

3' education - Sep. 28, 2009
##FULL_TITLE##

Intervening in CV Risk

3' education - July 29, 2009
##FULL_TITLE##

Glycemic control

3' education - July 29, 2009
##FULL_TITLE##

Hypertension and diabetes

3' education - July 29, 2009
##FULL_TITLE##

Opportunities for ARB’s

3' education - July 29, 2009
##FULL_TITLE##

Compliance in diabetes

3' education - July 29, 2009

On demand 10" video

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD
5 Things a cardiologist needs to know about GLP-1 RA

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD - Online CME
5 Things a cardiologist needs to know about GLP-1 RA

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD - Online CME

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD - Online CME
5 Things a cardiologist needs to know about GLP-1RA

Which patients to consider for GLP-1RA?

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD - Online CME

The role of GLP-1 receptor agonists in CVD prevention

10' education - Nov. 6, 2020 - Prof. Kamlesh Khunti, MD - Online CME

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

Introduction: Expanding focus for cardiologists - The patient with diabetes and cardiovascular outcomes

10' education - Oct. 3, 2020 - Prof. Ulf Landmesser, MD

Changing paradigm in prediabetes and CVD: Potential for new concepts and new tools

10' education - Sep. 28, 2020 - Prof. John E Deanfield, MD - Online CME

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD - Online CME

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD - Online CME

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada

Diabetes & CVD: Time for a multifactorial approach

10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD London, United Kingdom - Online CME

Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK - Online CME

Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Lina Badimon, MD Barcelona, Spain - Online CME

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden - Online CME

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK - Online CME

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK - Online CME

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France - Online CME

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland - Online CME

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands - Online CME

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

What are the key mechanisms of CV benefit of novel diabetes drugs?

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar - Online CME

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser - Online CME

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

Key classes of antidiabetic drugs – How do they work?

10' education - Feb. 14, 2018 - Prof Cliff Bailey - Birmingham, UK - Online CME

Diabetes cardiovascular outcome trials

10' education - Feb. 14, 2018 - Prof. Lawrence Leiter, MD - Toronto, ON, Canada - Online CME

HbA1c in CVD

10' education - Feb. 14, 2018 - Prof Naveed Sattar, MD - University of Glasgow, United Kingdom - Online CME

Natural history of DM: Focus on micro- and macrovascular complications

10' education - Feb. 13, 2018 - Prof. Kausik Ray, Imperial College London, UK - Online CME

Diabetic dyslipidemia and residual risk in the era of LDL control

10' education - Jan. 25, 2018 - Boston, MA, USA - Dr. Aruna Pradhan - Brigham & Women's Hospital, Boston, USA

Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

10' education - Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Insights from the first trials in epigenetics in human: What is the way forward?

10' education - Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017 - Online CME

Brief update on the LEADER cardiovascular outcomes trial

10' education - Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK

Management of CV Risk & T2DM: Implications of novel outcome trials

10' education - Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017 - Online CME

The Clinical Unmet need in the patient with Diabetes and ACS

10' education - Aug. 26, 2017 - Barcelona, Spain - Kausik Ray, MD Imperial College London United Kingdom - PACE-CME symposium held at ESC 2017 - Online CME

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

HF & Diabetes: SGLT2 inhibition a paradigm shift?

10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

Challenging cardiovascular risk in diabetes: ready for a new approach?

10' education - Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

10' education - Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

10' education - Aug. 28, 2016 - ESC 2016, Rome - Kausik Ray, MD – Imperial College London, United Kingdom - Recorded at PACE-CME symposium at ESC 2016

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Current treatment of Diabetes in Heart Failure

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands
##FULL_TITLE##

Diabetic dyslipidaemia and residual risk in the era of LDL control

10' education - Mar. 21, 2016 - Boston, MA, USA - Aruna Pradhan
##FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##FULL_TITLE##

SGLT2 inhibitor outcome trials: Future opportunities

10' education - Sep. 27, 2015 - London - Dr David Fitchet, Toronto, Canada
##FULL_TITLE##

SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

10' education - Sep. 29, 2015
##FULL_TITLE##

What is the story about Diabetes & CVD: Rationale for a multifactorial approach

10' education - Sep. 29, 2015
##FULL_TITLE##

Diabetes & Cardiovascular Disease:The risk factor to be challenged

10' education - Sep. 27, 2015
##FULL_TITLE##

Diabetes and reducing CVD: Are novel interventions living up to their promise?

10' education - Sep. 5, 2014 - Snapshot 2014 - Naveed Sattar MD, Glasgow

CV disease & diabetes in Asia

10' education - Apr. 15, 2013

Where do GLP-1RA fit in in current and future management of CKD?

Subtitling in English, German, Italian, Spanish and French

10' education - July 26, 2021 - Frederik Persson, MD - Online CME
Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities, Frederik Persson discusses future possibilities for use of GLP-1RA in other target populations.

Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities to reduce CV events, Frederik Persson discusses future possibilities for use of GLP-1RA. With question to test your knowledge.

Treatment goals for patients with T2DM and CKD

Subtitling in English, German, Italian, Spanish and French

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME
Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.

Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.

How can GLP-1RA benefit a patient with diabetes and CKD?

Subtitling in English, German, Italian, Spanish and French

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME
There is a need for therapies for patients with low eGFR. Daniël van Raalte discusses whether GLP-1RA therapy can provide benefit for patients with T2DM and CKD.

There is a need for therapies for patients with low eGFR. Daniël van Raalte discusses whether GLP-1RA therapy can provide benefit for patients with T2DM and CKD. With question to test your knowledge.

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME
What are practical challenges around initiation of SGLT2i therapy? What should a physician explain to a patient at the start of SGLT2i therapy? Alice Cheng answers these questions in this video.

What are practical challenges around initiation of SGLT2i therapy? What should a physician explain to a patient at the start of SGLT2i therapy? Alice Cheng answers these questions in this video. With question to test your knowledge.

Prevention strategies in patients with CKD and T2DM

Subtitling in English, German, Italian, Spanish and French

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME
Ofri Mosenzon discusses the importance of identification of CKD and how to prevent CKD progression in T2DM with older and newer therapeutic options.

Ofri Mosenzon discusses the importance of identification of CKD and how to prevent CKD progression in T2DM with older and newer therapeutic options. With question to test your knowledge.

Clinical inertia in CKD - What is the rationale for SGLT2i?

Subtitling in English, German, Italian, Spanish and French

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME
Janaka Karalliedde gives an overview of trials and guidelines that provide evidence for using SGLT2 inhibitors to improve outcomes in patients with CKD.

Janaka Karalliedde gives an overview of trials and guidelines that provide evidence for using SGLT2 inhibitors to improve outcomes in patients with CKD.

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD
A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

GLP-1RAs: What are the future directions in development?

Subtitling in English, German, Italian, Spanish, French, and Chinese

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD - Online CME
Prof. Deanfield discusses the changing paradigm for managing cardiometabolic risk in clinical practice by the emergence of diabetes. He states that GLP-1 receptor agonists will be an important component of treatment strategies.

5 Things a cardiologist needs to know about GLP-1 RA Prof. Deanfield discusses the changing paradigm for managing cardiometabolic risk in clinical practice by the emergence of diabetes. He states that GLP-1 receptor agonists will be an important component of treatment strategies.

What is the clinical evidence for the benefits of GLP-1RAs?

*NEW* Subtitling in English, German, Italian, Spanish, French, and Chinese

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD - Online CME
Prof. Verma discusses the CV results of clinical trials with GLP-1 RAs and how these translate to CV protection in T2D.

5 Things a cardiologist needs to know about GLP-1RA Prof. Verma discusses the CV results of clinical trials with GLP-1RAs and how these translate to CV protection in T2DM.

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD - Online CME
The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.

The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD
The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.

AHA 2020 The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.

Which patients to consider for GLP-1RA?

*NEW* Click on video for subtitling in English, German, Italian, Spanish, French, or Chinese.

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD - Online CME
Prof. Jacob discusses the shift in management of diabetes by a glycemic approach towards prevention of CV complications. He describes the evolution of the treatment recommendations in T2DM management.

5 Things a cardiologist needs to know about GLP-1RA Prof. Jacob discusses the shift in management of diabetes by a glycemic approach towards prevention of CV complications. He describes the evolution of the treatment recommendations in T2DM management.

The role of GLP-1 receptor agonists in CVD prevention

10' education - Nov. 6, 2020 - Prof. Kamlesh Khunti, MD - Online CME
There are barriers to intensify treatment in T2DM patients, leading to poor outcomes. Prof. Khunti presents findings from studies with GLP-1RA as a new, effective treatment option for T2DM patients with high CV risk.

There are barriers to intensify treatment in T2DM patients, leading to poor outcomes. Prof. Khunti presents findings from studies with GLP-1RA as a new, effective treatment option for T2DM patients with high CV risk.

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME
Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. Prof. Hobbs discusses the classic CV risk factors one by one.

Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. In this presentation, prof. Hobbs discusses the classic CV risk factors one by one.

Introduction: Expanding focus for cardiologists - The patient with diabetes and cardiovascular outcomes

10' education - Oct. 3, 2020 - Prof. Ulf Landmesser, MD
Prof. Landmesser gives an introduction to the symposium about managing diabetes in CV risk reduction, that was held during the virtual ESC 2020 congress.

Prof. Landmesser gives an introduction to the symposium about managing diabetes in CV risk reduction, that was held during the virtual ESC 2020 congress.

Changing paradigm in prediabetes and CVD: Potential for new concepts and new tools

Click on video for subtitling in English, German, Italian, Spanish, French, Chinese

10' education - Sep. 28, 2020 - Prof. John E Deanfield, MD - Online CME
Prof. Deanfield emphasizes the importance of early intervention to prevent T2DM and obesity and thereby reducing lifetime CV risk.

Prof. Deanfield emphasizes the importance of early intervention to prevent T2DM and obesity and thereby reducing lifetime CV risk.

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD
Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.

Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD
Patients with diabetic kidney disease (DKD) have an unmet residual CV risk. Prof. Stroes brings up some novel opportunities to treat this risk and elaborates on mechanisms of CV benefit by GLP-1RAs.

Patients with diabetic kidney disease (DKD) have an unmet residual CV risk. Prof. Stroes brings up some novel opportunities to treat this risk and elaborates on mechanisms of CV benefit by GLP-1RAs.

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD
The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.

ERA-EDTA 2020 The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020
COMPASS Diabetes compared treatment of low-dose rivaroxaban plus aspirin with aspirin alone in stable CAD and/or PAD patients with or without diabetes.

ACC 2020 COMPASS Diabetes compared treatment of low-dose rivaroxaban plus aspirin with aspirin alone in stable CAD and/or PAD patients with or without diabetes.

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD
Prof. Verma shares the data of subanalyses of the LEADER and SUSTAIN-6 trials on the effect of GLP-1RA treatment (liraglutide and semaglutide) in T2DM patients with peripheral artery disease.

Prof. Verma shares the data of subanalyses of the LEADER and SUSTAIN-6 trials on the effect of GLP-1RA treatment in T2DM patients with peripheral artery disease.

More insight into daily clinical practice and more collaboration needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD
Prof. Mathieu concludes that clinical practice lags behind regarding available evidence on management of T2DM. She considers what causes this gap and who needs to act to change it.

DIabetes summit Prof. Mathieu concludes that clinical practice lags behind regarding available evidence on management of T2DM. She considers what causes this gap and who needs to act to change it.

Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit
Prof. Cosentino considers the how and why of development of clinical guidelines, in light of new recommendations in the 2019 ESC/EASD diabetes guidelines.

Diabetes summit Prof. Cosentino considers the how and why of development of clinical guidelines, in light of new recommendations in the 2019 ESC/EASD diabetes guidelines.

Barriers to implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit
Prof. Lehmann considers factors that may play a role when diabetes guidelines are not adequately implemented, and how these barriers may be overcome.

Diabetes summit Prof. Lehmann considers factors that may play a role when diabetes guidelines are not adequately implemented, and how these barriers may be overcome.

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD
Prof. Ray gives a presentation on the rationale, design and CV outcomes of the BETonMACE trial, in which the BET inhibitor apabetalone was evaluated compared to placebo in high-risk patients.

Prof. Ray gives a presentation on the rationale, design and CV outcomes of the BETonMACE trial, in which the BET inhibitor apabetalone was evaluated compared to placebo in high-risk patients.

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD
Prof. Deanfield explains why these are exciting times for the management of CVD in patients with diabetes and also in those without diabetes.

Prof. Deanfield explains why these are exciting times for the management of CVD in patients with diabetes and also in those without diabetes.

Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM

5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD
Jan Westerink tells about an exploratory analysis of the Look AHEAD trial, using a new prediction model to assess heterogeneity of treatment effects of an intensive lifestyle intervention on occurence of CV events in T2DM.

CSI Paris Jan Westerink tells about an exploratory analysis of the Look AHEAD trial, using a new prediction model to assess heterogeneity of treatment effects of an intensive lifestyle intervention on occurence of CV events in T2DM.

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD
Prof. Zannad gives an overview of CV outcome trials with SGLT2 inhibitors; first in diabetes patients and now with results in HF patients in the DAPA-HF trial.

Prof. Zannad gives an overview of CV outcome trials with SGLT2 inhibitors; first in diabetes patients and now with results in HF patients in the DAPA-HF trial.

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD
Before listing the differences between the AHA/ACC 2018 and ESC/EAS 2019 dyslipidemia guidelines, prof. Ballantyne shares common themes and shared concept across the guidelines.

Before listing the differences between the AHA/ACC 2018 and ESC/EAS 2019 dyslipidemia guidelines, prof. Ballantyne shares common themes and shared concept across the guidelines.

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD
Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.

ESC 2019 Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD
Prof. Sattar shows that CV risk is heterogenous in patients with diabetes, and explains why new diabetes drugs, such as GLP-1RAs, are recommended for patients with diabetes and CV risk.

Prof. Sattar shows that CV risk is heterogenous in patients with diabetes, and explains why new diabetes drugs, such as GLP-1RAs, are recommended for patients with diabetes and CV risk.

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner
Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.

Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD
Prof. Ray describes the high residual CV risk in post-ACS diabetes patients, and how BET inhibition with apabetalone may reduce this residual risk and thereby prevent CV events.

Prof. Ray describes the high residual CV risk in post-ACS diabetes patients, and how BET inhibition with apabetalone may reduce this residual risk and thereby prevent CV events.

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD
As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.

ESC 2019 As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME
Prof. Steg presents data of the ODYSSEY Outcomes trial in specific subgroups of ACS patients that benefit most from alirocumab therapy, and discusses the effect of this PCSK9 inhibitor by baseline Lp(a) levels.

Prof. Steg presents data of the ODYSSEY Outcomes trial in specific subgroups of ACS patients that benefit most from alirocumab therapy, and discusses the effect of this PCSK9 inhibitor by baseline Lp(a) levels.

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg
The THEMIS study evaluated the effect of ticagrelor vs. placebo on top of aspirin in diabetes patients with stable coronary artery disease. Netto clinical benefit depended on having a history of PCI or not.

ESC 2019 The THEMIS study evaluated the effect of ticagrelor vs. placebo on top of aspirin in diabetes patients with stable coronary artery disease. Netto clinical benefit depended on having a history of PCI or not.

DAPT strategy results in favorable net clinical benefit in CAD patients with diabetes and prior PCI

3' education - Sep. 1, 2019 - Prof. Deepak Bhatt
In diabetes patients with stable CAD, ticagrelor plus aspirin resulted in reduced CV outcomes, but at the cost of increased bleeding. Net clinical benefit was favorable in a prespecified subgroup of patients with prior PCI.

ESC 2019 In diabetes patients with stable CAD, ticagrelor plus aspirin resulted in reduced CV outcomes, but at the cost of increased bleeding. Net clinical benefit was favorable in a prespecified subgroup of patients with prior PCI.

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME
Prof. Knop describes the possible mechanisms of CV/CKD risk reduction by GLP-1 receptor activation.

Prof. Knop describes the possible mechanisms of CV/CKD risk reduction by GLP-1 receptor activation.

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME
Paola Fioretto discusses possible underlying mechanisms of the nephroprotective effects of SGLT2i, as observed in large clinical trials.

Paola Fioretto discusses possible underlying mechanisms of the nephroprotective effects of SGLT2i, as observed in large clinical trials.

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD - Online CME
Frederik Persson shows evidence of renoprotective effects with GLP-1RA treatment, by discussing various small clinical trials as well as CVOTs with GLP-1RAs.

Frederik Persson shows evidence of renoprotective effects with GLP-1RA treatment, by discussing various small clinical trials as well as CVOTs with GLP-1RAs.

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD - Online CME
We have entered a new era for treatment of cardiorenal disease in diabetes. Prof. John Deanfield discusses evidence on the need for early management and alteration of upstream factors that affect renal and cardiac function in diabetic patients.

We have entered a new era for treatment of cardiorenal disease in diabetes. Prof. John Deanfield discusses evidence on the need for early management and alteration of upstream factors that affect renal and cardiac function in diabetic patients.

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD
Prof. McMurray gives an update on where we are today in the prevention of HF in diabetes patients with new diabetes drugs and talks about the next steps of treating HF in patients with and without diabetes.

Prof. McMurray gives an update on where we are today in the prevention of HF in diabetes patients with new diabetes drugs and talks about the next steps of treating HF in patients with and without diabetes.

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME
Prof. Agarwal discusses the current standard of care  in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.

Prof. Agarwal discusses the current standard of care in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD
Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.

Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD
Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how we can modify CVD risk factors in these patients.

EuroPrevent 2019 Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how we can modify CVD risk factors in these patients.

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD
Prof. Jacob discusses the shift in management of diabetes based on CVOTs and explains underlying mechanisms of benefits with GLP-1RAs in diabetic patients.

EuroPrevent 2019 Prof. Jacobs discusses the shift in management of diabetes based on CVOTs and explains underlying mechanisms of benefits with GLP-1RAs in diabetic patients.

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD
Prof. Adriaan Voors addresses three major questions on the future of SGLT2i in HF: on routine use in T2DM and HF, use in HF without T2DM, and ongoing trials.

Prof. Adriaan Voors addresses three major questions on the future of SGLT2i in HF: on routine use in T2DM and HF, use in HF without T2DM, and ongoing trials.

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore
Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.

Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD
Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.

ISN-WCN 2019 Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK
What should cardiologists know about diabetes in HF patients? Martin Cowie gives an overview of how to detect and treat diabetes in HF patients.

What should cardiologists know about diabetes in HF patients? Martin Cowie gives an overview of how to detect and treat diabetes in HF patients.

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada
Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.

ISN-WCN 2019 Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.

Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR

3' education - Apr. 17, 2019
Use of canagliflozin in T2DM patients with kidney disease resulted in reduction of renal and CV outcomes, irrespective of baseline kidney dysfunction. Prof Carol Pollock discusses the results of the CREDENCE trial.

ISN-WCN 2019 Use of canagliflozin in T2DM patients with kidney disease resulted in reduction of renal and CV outcomes, irrespective of baseline kidney dysfunction. Prof Carol Pollock discusses the results of the CREDENCE trial.

Reduction in renal outcomes with selective endothelin receptor antagonist in patients with diabetic kidney disease

3' education - Apr. 17, 2019 - Melbourne, Australia
Prof. Hiddo Lambers Heerspink dissusses the unique design of the SONAR trial and the findings with atrasentan therapy in patients with diabetic kidney disease.

ISN-WCN 2019 Prof. Hiddo Lambers Heerspink dissusses the unique design of the SONAR trial and the findings with atrasentan therapy in patients with diabetic kidney disease.

Endothelin receptor antagonist gives renoprotection in selected patients with T2DM and CKD

3' education - Apr. 15, 2019 - Melbourne, Australia
The SONAR trial was designed to safely test the effect of atrasentan in a selected group of high-risk T2DM patients with kidney disease. This proved to be a good approach, as results were very positive.

ISN-WCN 2019 The SONAR trial was designed to safely test the effect of atrasentan in a selected group of high-risk T2DM patients with kidney disease. This proved to be a good approach, as results were very positive.

Hopeful results with SGLT2 inhibitor in patients with T2DM and chronic kidney disease

3' education - Apr. 15, 2019 - Melbourne, Australia
Prof. Perkovic summarizes the results of the CREDENCE trial that tested the SGLT2 inhibitor canagliflozin. It is a safe drug that prevents kidney failure and CV complications in people with diabetes and kidney disease.

ICN-WCN 2019 Prof. Perkovic summarizes the results of the CREDENCE trial that tested the SGLT2 inhibitor canagliflozin. It is a safe drug that prevents kidney failure and CV complications in people with diabetes and kidney disease.

Two choices of drugs that reduce CV risk in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD
Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Diabetes & CVD: Time for a multifactorial approach

10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD London, United Kingdom - Online CME
Prof. Deanfield sheds light on the relation between T2DM and CVD, and how studies evaluating novel classes of antidiabetic drugs have evolved over time, from revealing safety signals to demonstrating CV benefit.

Prof. Deanfield sheds light on the relation between T2DM and CVD, and how studies evaluating novel classes of antidiabetic drugs have evolved over time, from revealing safety signals to demonstrating CV benefit.

Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK - Online CME
Prof. Neil Poulter discusses lessons that can be drawn from recent CVOTs on treatment and prevention strategies in patients with CV risk and T2DM.

Prof. Neil Poulter discusses lessons that can be drawn from recent CVOTs on treatment and prevention strategies in patients with CV risk and T2DM.

Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Lina Badimon, MD Barcelona, Spain - Online CME
Prof. Lina Badimon discusses several lines of evidence on the beneficial effects of novel antidiabetic therapeutic strategies that affect multiple body systems in addition to glucose metabolism.

Prof. Lina Badimon discusses several lines of evidence on the beneficial effects of novel antidiabetic therapeutic strategies that affect multiple body systems in addition to glucose metabolism.

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD
Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits.

Cardio Diabetes Masterclass Dubai Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits .

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD
Prof. Montanya DMdiscusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trials, respectively.

Cardio Diabetes Masterclass Dubai Prof. Montanya discusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trial, respectively.

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden - Online CME
Different GLP-1RAs have shown different effects in CV outcomes trials. Prof Rydén scrutinizes the results of the trials to learn more about the effects of individual GLP-1RAs and what the differences may originate from.

Different GLP-1RAs have shown different effects in CV outcomes trials. Prof Rydén scrutinizes the results of the trials to learn more about the effects of individual GLP-1RAs and what the differences may originate from.

SGLT2 inhibitor treatment may now be considered in broader T2DM population

AHA 2018 - Chicago, IL, VS

3' education - Nov. 11, 2018 - Steve Wiviott, MD - Boston, MA, VS.
Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.

AHA 2018 Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany
Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.

Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany
Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.

Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands
Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CVD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.

Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CVD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.

In a primary prevention setting of diabetes patients, aspirin did not give overall benefit

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK
Although aspirin resulted in a reduction of CV events in a primary prevention setting of diabetes patients, this CV benefit was counterbalanced by an increase in bleeding.

ESC 2018 Although aspirin resulted in a reduction of CV events in a primary prevention setting of diabetes patients, this CV benefit was counterbalanced by an increase in bleeding.

Weight loss agent showed CV safety in high-risk patients with overweight or obesity

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US
In overweight or obese patients with CVD or diabetes with one CV risk factor, lorcaserin demonstrated to be safe with respect to CV outcomes. Dr Bohula discussed the details of the CAMELLIA-TIMI 61 trial.

ESC 2018 In overweight or obese patients with CVD or diabetes with CV risk factors, lorcaserin demonstrated to be safe with respect to CV outcomes. Dr. Bohula discussed the details of the CAMELLIA-TIMI 61 trial.

No CV benefit with omega-3 fatty acid supplements

3' education - Aug. 26, 2018
Use of omega-3 fatty acid supplements did not result in reduction of CV outcomes in the ASCEND trial, a large, randomized, long-term trial of diabetes patients.

ESC 2018 Use of omega-3 fatty acid supplements did not result in reduction of CV outcomes in the ASCEND trial, a large, randomized, long-term trial of diabetes patients.

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK
Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.

Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK - Online CME
Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.

Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK - Online CME
Until recently, ESC Guidelines said little about management of patients with HF and T2DM. New treatment options have now become available. Prof. Cowie considers how cardiologists can be involved in T2DM care in their patients.

Until recently, ESC Guidelines said little about management of patients with HF and T2DM. New treatment options have now become available. Prof. Cowie considers how cardiologists can be involved in T2DM care in their patients.

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France - Online CME
Prof. Zannad carefully considers the trial results of novel antidiabetic drugs and speculates how they may have yielded their clinical effects, and which patients may benefit from them.

Prof. Zannad carefully considers the trial results of novel antidiabetic drugs and speculates how they may have yielded their clinical effects, and which patients may benefit from them.

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland - Online CME
Prof. Per-Henrik Groop explores the mechanisms and outcomes of SGLT2 inhibition in diabetic kidney disease.

Prof. Per-Henrik Groop explores the mechanisms and outcomes of SGLT2 inhibition in diabetic kidney disease.

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME
Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK
A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.

A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden - Online CME
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands - Online CME
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and additional effects observed in recent outcome trials of newer agents.

Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and additional effects observed in recent outcome trials of newer agents.

Translation of novel approaches in CVD & diabetes to clinical practice

Expert Meeting on CVD & T2DM

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME
Three cardiology and diabetes experts consider how the paradigma-shifting recent insights on the new antidiabetic drug classes can be implemented into clinical practice, which should involve a more multidisciplinary approach.

Three cardiology and diabetes experts consider how the paradigma-shifting recent insights on the new antidiabetic drug classes can be implemented into clinical practice, which should involve a more multidisciplinary approach.

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Prof. Hobbs stresses  the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands
Charlotte Koopal discusses the pathofysiology of familial dysbetalipoproteinemia, how to diagnose the disease and recommendations for treatment.

Charlotte Koopal discusses the pathofysiology of familial dysbetalipoproteinemia, how to diagnose the disease and recommendations for treatment.

Novel diabetes drugs in clinical management: Extending the opportunities

Expert Meeting on CVD & T2DM

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME
Three cardiology and diabetes experts speculate on how GLP-1 RAs and SGLT2 inhibitors may be benefitted from to lower CV risk, beyond treatment of T2DM patients. Also; may they be used simultaneously?

Three cardiology and diabetes experts speculate on how GLP-1 RAs and SGLT2 inhibitors may be benefitted from to lower CV risk, beyond treatment of T2DM patients. Also; may they be used simultaneously?

What are the key mechanisms of CV benefit of novel diabetes drugs?

Expert Meeting on CVD & T2DM

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar - Online CME
Three cardiology and diabetes experts discuss what can be learned from trial results about mechanisms underlying the CV benefits seen with the novel antidiabetic drugs, and which questions remain unanswered.

Three cardiology and diabetes experts discuss what can be learned from trial results about mechanisms underlying the CV benefits seen with the novel antidiabetic drugs, and which questions remain unanswered.

What is the science driving CVD and T2DM?

Expert Meeting on CVD & T2DM

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser - Online CME
Three cardiology and diabetes experts discuss the multifactorial aspect of type 2 diabetes, and the consequential challenges in cardiovascular prevention and management.

Three cardiology and diabetes experts discuss the multifactorial aspect of type 2 diabetes, and the consequential challenges in cardiovascular prevention and management of these patients.

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK
Atherogenic dyslipidemia increases CV risk in diabetes patients. Prof. Ray discusses the importance of dyslipidemia in these patients, the associated CV risk and new medical therapies to reduce this risk.

Atherogenic dyslipidemia increases CV risk in diabetes patients. Prof. Ray discusses the importance of dyslipidemia in these patients, the associated CV risk and new medical therapies to reduce this risk.

Hypoglycemia in cardiovascular medicine: why worry?

5 Things a cardiologist needs to know about diabetes

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME
Several factors make a diabetes patient more vulnerable to severe hypoglycemia events, which are associated with higher CV morbidity and mortality. Prof Schernthaner discusses how hypoglycemia can be prevented.

5 Things a cardiologist needs to know about diabetes Several factors make a diabetes patient more vulnerable to severe hypoglycemia events, which are associated with higher CV morbidity and mortality. Prof Schernthaner discusses how hypoglycemia can be prevented.

Key classes of antidiabetic drugs – How do they work?

5 Things a cardiologist needs to know about diabetes

10' education - Feb. 14, 2018 - Prof Cliff Bailey - Birmingham, UK - Online CME
Multiple causal pathways contribute to development of T2DM, thus various processes may be targeted to improve glucose regulation. Prof. Bailey briefly summarises the available therapeutic options.

5 Things a cardiologist needs to know about diabetes Multiple causal pathways contribute to development of T2DM, thus various processes may be targeted to improve glucose regulation. Prof. Bailey briefly summarises the available therapeutic options.

Diabetes cardiovascular outcome trials

5 Things a cardiologist needs to know about diabetes

10' education - Feb. 14, 2018 - Prof. Lawrence Leiter, MD - Toronto, ON, Canada - Online CME
Prof Leiter gives an update of the trials on new antihyperglycemic drugs that have been completed or are ongoing since the FDA mandated demonstration of CV safety. Trials evaluating DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors on CV outcomes are being discussed.

5 Things a cardiologist needs to know about diabetes Prof Leiter gives an update of the trials on new antihyperglycemic drugs (DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors) that have been completed or are ongoing since the FDA mandated demonstration of CV safety.

HbA1c in CVD

5 Things a cardiologist needs to know about diabetes

10' education - Feb. 14, 2018 - Prof Naveed Sattar, MD - University of Glasgow, United Kingdom - Online CME
Prof Naveed Sattar discusses the value of HbA1c to diagnose T2DM, and how HbA1c levels are related to the risk of developing micro and macrovascular disease and the consequences thereof for choosing a HbA1c therapeutic target.

5 Things a cardiologist needs to know about diabetes Prof Naveed Sattar discusses the value of HbA1c to diagnose T2DM, and how HbA1c levels are related to the risk of developing micro and macrovascular disease and the consequences thereof for choosing a HbA1c therapeutic target.

Natural history of DM: Focus on micro- and macrovascular complications

5 Things a cardiologist needs to know about diabetes

10' education - Feb. 13, 2018 - Prof. Kausik Ray, Imperial College London, UK - Online CME
Prof. Ray focuses on micro- and macrovascular disease in type 2 diabetes, their implications, their interrelationship and how these risks can be modified by new glucose-lowering agents.

5 Things a cardiologist needs to know about diabetes Prof. Ray focuses on micro- and macrovascular disease in type 2 diabetes, their implications, their interrelationship and how these risks can be modified by new glucose-lowering agents.

Diabetic dyslipidemia and residual risk in the era of LDL control

10' education - Jan. 25, 2018 - Boston, MA, USA - Dr. Aruna Pradhan - Brigham & Women's Hospital, Boston, USA
Dr. Aruna Pradhan describes the role of triglyceride lowering in reducing CV risk in patients with T2DM.

Dr. Aruna Pradhan describes the role of triglyceride lowering in reducing CV risk in patients with T2DM.

Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

10' education - Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA
Dr. Stephen Wiviott explains how a change in regulatory guidance has dramatically altered the trial landscape and drug development for type 2 diabetes mellitus and has provided substantial information related to CV disease.

Dr. Stephen Wiviott explains how a change in regulatory guidance has dramatically altered the trial landscape and drug development for type 2 diabetes mellitus and has provided substantial information related to CV disease.

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

New therapeutic options can make a difference for diabetic patients with high CV risk

3' education - Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK
Prof. John Deanfield states that the introduction of two new drug classes with CV benefits can really make a difference for the CV outcomes of high-risk diabetic patients

Prof. John Deanfield states that the introduction of two new drug classes with CV benefits can really make a difference for the CV outcomes of high-risk diabetic patients

Cardiovascular protection in type 2 diabetes

5' education - Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden
Prof. Lars Rydén describes two classes of drugs that may protect patients with type 2 diabetes from CV events. Depending on the type of patient, cardiologists can choose  a drug.

Prof. Lars Rydén describes two classes of drugs that may protect patients with type 2 diabetes from CV events. Depending on the type of patient, cardiologists can choose a drug.

Insights from the first trials in epigenetics in human: What is the way forward?

10' education - Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017 - Online CME
Lecture by Prof Stephen Nicholls held at symposium on BET Inhibition: Managing high risk diabetes patient with cardiovascular disease: What works, and what else can we do?

This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017

Brief update on the LEADER cardiovascular outcomes trial

10' education - Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK
Prof. Neil Poulter gives a brief overview of the design and results of the LEADER CV outcomes trial with the GLP-1 agonist liraglutide.

Prof. Neil Poulter gives a brief overview of the design and results of the LEADER CV outcomes trial with the GLP-1 agonist liraglutide.

Management of CV Risk & T2DM: Implications of novel outcome trials

10' education - Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017 - Online CME

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017

The Clinical Unmet need in the patient with Diabetes and ACS

10' education - Aug. 26, 2017 - Barcelona, Spain - Kausik Ray, MD Imperial College London United Kingdom - PACE-CME symposium held at ESC 2017 - Online CME
Lecture by Prof Kausik Ray held at symposium on BET Inhibition: Managing high risk diabetes patient with cardiovascular disease: What works, and what else can we do?

This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA
Kamyar Kalantar-Zade, MD shows the data based on which alkaline phosphatase is emerging as a prognostic biomarker of CV events. BET inhibition with apabetalone lowers ALP, and may thus be a promising therapeutic strategy.

Kamyar Kalantar-Zade, MD shows the data based on which alkaline phosphatase is emerging as a prognostic biomarker of CV events. BET inhibition with apabetalone lowers ALP, and may thus be a promising therapeutic strategy.

Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain
Marta Ruiz-Ortega sheds light on the new and exciting field of epigenetics, and how BET inhibition might provide an interesting therapeutic target in renal disease. She shares experimental data dat demonstrate the beneficial effects of BET inhibition.

Marta Ruiz-Ortega sheds light on the new and exciting field of epigenetics, and how BET inhibition might provide an interesting therapeutic target in renal disease. She shares experimental data dat demonstrate the beneficial effects of BET inhibition.

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain
Luis M Ruilope, MD looks at the evidence showing that currently available therapies leave room for improvement in the reduction of CV events in patients with diabetes and chronic kidney disease.

Luis M Ruilope, MD looks at the evidence showing that currently available therapies leave room for improvement in the reduction of CV events in patients with diabetes and chronic kidney disease.

UK: Clinical Dialogues: Lipids & Diabetes 2017

3' education - July 7, 2017 - Stratford Upon Avon, United Kingdom - Prof Peter Sever

Invitation by Prof Peter Sever to attend the Clinical Dialogue on Lipids & Diabetes to be held on December 6 & 7 in Stratford Upon Avon, United Kingdom

How incretin therapy changes diabetes and prediabetes management

3' education - May 22, 2017
Dr. Rajagopalan considers how the emergence of GLP-1 agonists, DPP-4 inhibitors and SGLT2 inhibitors has caused a sea change in the mangement of diabetes towards a broader approach to address CV risk.

VBWG ACC 2017 Dr. Rajagopalan considers how the emergence of GLP-1 agonists, DPP-4 inhibitors and SGLT2 inhibitors has caused a sea change in the mangement of diabetes towards a broader approach to address CV risk.

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris
Prof. Martin Cowie discusses the relationship between diabetes and renal dysfunction and the cardiovascular effect of new therapeutic classes to control diabetes in high-risk patients.

Diabetes and renal dysfunction are very common in patients with heart failure. Prof. Martin Cowie discusses the relationship and the cardiovascular effect of new therapeutic classes to control diabetes in high-risk patients.

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris
Prof. Per-Henrik Groop explains the clinical implications of SGLT2-inhibtion, based on EMPA REG Outcome.

Diabetes and diabetic kidney disease are associated with increased risk of cardiovascular disease and remarkably shortened life expectancy. Prof. Per-Henrik Groop explains the clinical implications of SGLT2-inhibtion, based on EMPA REG Outcome.

New diabetes treatments with CV benefit: A changing role for the cardiologist

3' education - Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)
Dr. Robert J Chilton, MD, argues that new diabetes treatments showing cardiovascular benefit require a different role of the cardiologist.

Dr. Robert J Chilton, MD, argues that new diabetes treatments showing cardiovascular benefit require a different role of the cardiologist. The SGLT2 inhibitor empagliflozin, for example, shows both cardiovascular and renal protection, in addition to lowering glucose.

Modifying CV risk by managing diabetes

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)
Dr. Jorge Plutzky, MD, discusses the ability to modulate and modify CV risk with new antidiabetic agents

Dr. Jorge Plutzky, MD, discusses the ability to modulate and modify CV risk with new antidiabetic agents. The use of an SGLT2 inhibitor or a GLP1 agonist should be considered in appropriate patients with diabetes.

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)
CV benefit that can be achieved with the new glucose-lowering SGLT2-inhibitor empagliflozin in diabetes

CSI Rome Manon Slob and Shahnam Sharif extensively discuss the results of the EMPA-REG OUTCOME study, the first outcomes trial with an SGLT2 inhibitor, with Prof. Silvio Inzucchi, including what the results may mean for the management of diabetes.

Update on SGLT2 inhibition in T2DM: A closer look at EMPA-REG OUTCOME

Lecture - July 31, 2016 - Asian Interchange on Diabetes - David Fitchett, MD – University of Toronto, Canada
A detailed look at the CV benefits of the EMPA-REG OUTCOME trial and possible underlying mechanisms, and whether other patient populations may also benefit from empagliflozin treatment.

David Fitchett discusses the CV benefits of the EMPA-REG OUTCOME trial in detail, and considers the possible underlying mechanisms, and whether other patient populations may also benefit.

CV Protection in the EMPA-REG OUTCOME Trial: A ‘Thrifty Substrate’ Hypothesis

Lecture - July 31, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research
A newly proposed hypothesis to explain the observed CV benefit of empagliflozin, involves increased haematocrit and higher ketone bodies as a potent alternative energy source.

Michael Mark proposes a new hypothesis that may explain the observed CV benefit of empagliflozin, involving increased haematocrit and higher ketone bodies as a potent alternative energy source.

Update on DPP4 inhibition in T2DM: Implications from recent and ongoing trials

Lecture - July 31, 2016 - Asian Interchange on Diabetes meeting - Richard E. Pratley, MD – Florida Hospital Diabetes Institute, Orlando, Fl, USA
Different DPP4 inhibitors have different pharmacological properties and hence different metabolic effects. Some of these properties allow their use in special patient groups.

Richard Pratley takes a close look at the different pharmacological properties of DPP4 inhibitors, and how these may explain why they may be suitable in special patient groups.

Understanding Diabetic Kidney Disease: What are the best options for clinical management?

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Per-Henrik Groop, MD – University of Helsinki, Helsinki, Finland

Dr. Per-Henrik Groop outlines that diabetic kidney disease is common and associated with a grim prognosis. Optimal glucose control is central to limiting the risk of renal complications. Newer antidiabetic drugs can play a welcome role to optimally treat these patients.

Diabetes and Cardiovascular Disease: A review of new outcome data impacting practice

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - David Fitchett, MD – University of Toronto, Canada

Dr. David Fitchett recalls the history of outcome trials of antidiabetic drugs, culminating in the clear CV benefit obtained with an SGLT2 inhibitor recently shown in the EMPA-REG OUTCOME trial.

Need for ongoing clinical innovation in management of T2DM: A closer look at the development process of new entities

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research

Michael Mark illustrates the full trajectory of development of the SGLT2 inhibitor empagliflozin, from finding a therapeutic target through testing clinical effects of the newly developed therapeutic agent.

Management of hyperglycemia in type 2 diabetes: Update on novel trends and developments

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Richard E. Pratley, MD – Florida Hospital Diabetes Institute, Orlando, FL, USA

Richard E. Pratley elaborates on the mechanisms of action, effects and outcomes of the many different classes of antidiabetic drugs that are currently available, and how they can be combined to maximise their effect.

Diabetes in Asia: What is different from the west?

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Chaicharn Deerochanawong, MD – Rajavithi Hospital College of Medicine, Bangkok, Thailand

Chaicharn Deerochanawong, MD (Bangkok, Thailand) elaborates on aspects of the diabetes phenotype that are different in Asia, as compared with the rest of the world. These differences affect management of diabetes patients.

HF & Diabetes: SGLT2 inhibition a paradigm shift?

10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome
Heart Failure & Diabetes: SGLT2 inhibition a paradigm shift?

John McMurray, MD, describes how SGLT2 inhibitors may work in preventing heart failure in diabetes.

Challenging cardiovascular risk in diabetes: ready for a new approach?

10' education - Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

10' education - Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome
SGLT-2 inhibitors in T2DM management: current position & future promise

Silvio Inzucchi reviews the role of new medications for diabetes, and in particular the SGLT2 inhibitors, and the results of the EMPA-REG OUTCOMR study

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

10' education - Aug. 28, 2016 - ESC 2016, Rome - Kausik Ray, MD – Imperial College London, United Kingdom - Recorded at PACE-CME symposium at ESC 2016

ESC 2016 There are several treatment targets for patients with diabetes and high CV risk. Kausik Ray gives an overview of treatment targets and introduces BET-inhibition as a novel treatment target.

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##KEY_PHRASE##

Good glycaemic control can now be achieved with a lower risk of hypoglycaemia than before. Prof. Groop elaborates on the evidence on whether improving glycaemic control with DPP-4 inhibitors translates into a reduction of renal complications.

A changing treatment paradigm in diabetes

3' education - July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)
##KEY_PHRASE##

Recent outcome studies have shown evidence for a CV benefit with novel antidiabetic therapies such as DPP4 inhibitors and SGLT2 inhibitors. Dr. Pratley summarises the observations and speculates on how these findings may affect treatment of patients with diabetes in the near future.

SGLT2 inhibition in diabetic kidney disease

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)

Very recently, data became available of use of the SGLT2-inhibitor empagliflozin in patients with diabetic kidney disease, a condition associated with increased risk of CV complications. Prof. Groop shares the data that suggest that empagliflozin can reduce or prevent the onset of this condition.

Exciting times in diabetes treatment: new drug class moves beyond glucose reduction

3' education - Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom
##KEY_PHRASE##

Recent outcome trials of novel antidiabetic drugs shed new light on why diabetes patients develop heart disease. Naveed Sattar predicts how this may change diabetes management.

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

ESC HF 2016 Conventional therapies to treat hyperkalemia are associated with clinical complications. Peter van der Meer discusses the mechanism and efficacy and safety results of two new therapeutic options that lower potassium levels: patiromer and ZS-9.

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

ESC HF 2016 David Fitchett discusses the results of the EMPA-REG OUTCOME trial: the first published trial evaluating CV endpoints with an SGLT2 inhibitor.

Current treatment of Diabetes in Heart Failure

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands

ESC HF 2016 Patients with both HF and diabetes have poor prognosis. Adriaan Voors reviews which currently available therapies provide benefit and which may increase risk in these patients.

New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA
New therapies for type 2 diabetes show CV event reduction, in addition to their glucose-lowering effect.

Silvio Inzucchi summarises recent developments in treatment of type 2 diabetes. Some new agents yield clear CV event risk reduction, while older glucose-lowering medication only had a moderate effect on CV events.

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

3' education - May 10, 2016 - David Fitchett, MD, University of Toronto, Canad
##KEY_PHRASE##

Dr Fitchett provides his perspective on the potential impact of the EMPA REG outcomes trial on the management of T2DM by cardiologists.

CV protection by SGLT2 inhibition: Potential mechanisms for benefit

3' education - May 10, 2016 - Kuala Lumpur, Malaysia - Prof Hiddo Lambers Heerspink, Groningen, The Netherlands

Prof Lambers Heerspink reviews potential mechanisms beyond glucose lowering, explaining the positive cardiovascular outcomes of SGLT2 inhibition as seen in the EMPA REG Outcomes trial.

Review of cardiovascular safety of DPP4 inhibitors

3' education - May 6, 2016 - Dubai, UAE - Dr Sanjay Rajagopalan, MD, Maryland
##KEY_PHRASE##

Dr Rajagopalan, MD, Maryland, USA reviews the utility of DPP4 inhibitors in T2DM patients with high CVD risk.

Stroke reduction with PPAR-Y antagonist pioglitazone

3' education - May 6, 2016 - Dubai, UAE - Dr Robert J Chilton
##KEY_PHRASE##

Dr. Robert Chilton, (Texas) discusses the results of the IRIS trial where treatment with PPAR-γ agonist pioglitazone

Diabetic dyslipidaemia and residual risk in the era of LDL control

10' education - Mar. 21, 2016 - Boston, MA, USA - Aruna Pradhan
##KEY_PHRASE##

Aruna Pradhan (Boston, MA, USA) shows why residual risk is substantial in diabetic patients, despite statin therapy, and considers how this may be targeted by modifying triglyceride levels and/or the PPAR pathway.

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##KEY_PHRASE##

The REACH registry demonstrated that CV risk factors are not adequately controlled worldwide. Prof. Deepak Bhatt (Boston, MA, USA) shares the evidence for preventive strategies and considers how the new PCSK9 inhibitors fit into CV risk management.

Recent advances in lowering CV risk with antidiabetic agents

3' education - Feb. 12, 2016 - Boston, MA, USA - Prof Stephen Wiviott
##KEY_PHRASE##

Prof Stephen Wiviott (Boston, MA, USA) summarises recent advances in development of antidiabetic agents that not only lower glucose but also reduce CV events.

CV outcomes with medicines to control glycemia: highlights from recently completed trials

3' education - Feb. 2, 2016 - VBWG, Orlando - Darren K. McGuire, MD
##KEY_PHRASE##

In response to a requirement of regulatory bodies for antidiabetic trials to now include CV outcomes assessment, data of 5 such outcomes trials are now available. Dr. McGuire (Dallas, TX, USA) summarises the results.

The mechanism of SGLT2 inhibition in glucose control

Nov. 24, 2015

A mechanism of action animation of SGLT2-inhibition, a diabetes therapy that directly targets glucose by reducing renal glucose reabsorption, independently of beta cell function and insulin resistance

Antidiabetic therapy reduces CV mortality and HF outcomes in high-risk patients

3' education - Nov. 10, 2015 - AHA 2015, Orlando, FL, USA - Prof. Silvio Inzucchi
##KEY_PHRASE##

AHA 2015 Prof. Silvio Inzucchi (Yale Diabetes Center, New Haven, CT, USA) presented the HF outcomes on the large CV outcome EMPA-REG OUTCOME trial, which evaluated treatment with SGLT2-inhibitor empagliflozin in patients with diabetes.

SGLT2 inhibitor outcome trials: Future opportunities

Dr David Fitchett

10' education - Sep. 27, 2015 - London - Dr David Fitchet, Toronto, Canada
##KEY_PHRASE##

Dr Fitchett discusses the unmet glycemic control needs, the ongoing clinical trials with SGLT2 inhibitors and the EMPA-REG OUTCOME trial

SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

Prof Silvio E Inzucchi, Yale Diabetes Center, New Haven, CT, USA

10' education - Sep. 29, 2015
##KEY_PHRASE##

Prof Inzucchi provides an overview on SGLT2 inhibition, how they work and what are the potential pathways for cardiovascular benefits

What is the story about Diabetes & CVD: Rationale for a multifactorial approach

Prof John Betteridge, London UK

10' education - Sep. 29, 2015
##KEY_PHRASE##

Prof John Betteridge reviews the rationale for cardiovascular risk factor management in diabetes

Diabetes & Cardiovascular Disease:The risk factor to be challenged

Prof John E Deanfield, London, UK

10' education - Sep. 27, 2015
##KEY_PHRASE##

Prof Deanfield discusses the rationale for glucose control and CV risk reduction

Cardiovascular effects of glucose lowering: Safety vs Efficacy

3' education - Dec. 12, 2014 - AHA, Chicago VBWG - Dr Silvio E Inzucchi
##KEY_PHRASE##

Dr. Inzucchi, New Haven, provides his perspective on current diabetes therapies and ongoing trials with DPP4 and SGLT2 inhibitors on cardiovascular safety and/or benefits

What do novel diabetes drugs add to CV risk reduction?

3' education - Oct. 19, 2014 - Snapshot 2014 - Dr Naveed Sattar
##KEY_PHRASE##

Prof. Naveed Sattar, Glasgow, UK provides his view on the potential role of novel diabetes drugs in CV risk management

Diabetes and reducing CVD: Are novel interventions living up to their promise?

Naveed Sattar, MD, Glasgow, United Kingdom

10' education - Sep. 5, 2014 - Snapshot 2014 - Naveed Sattar MD, Glasgow
##KEY_PHRASE##

Lecture held by Prof Naveed Sattar, MD, Glasgow, United Kingdom on 'Diabetes and reducing CVD: Are novel interventions living up to their promise?' held  during the PACE 2014 Snapshot session in Barcelona

Neurological complications in diabetes

3' education - Apr. 23, 2014 - CDMC Almaty - Boris Mankovsky
##KEY_PHRASE##

Dr. Boris Mankovsky, Kiev, Ukrain describes the importance to address neurological complications in patients with diabetes, such as diabetic neuropathy, brain damage and stroke.

Impact of new diabetes drugs on cardiovascular outcomes

3' education - Apr. 18, 2014 - VBWG - ACC 2014 - Deepak L. Bhatt
##KEY_PHRASE##

Dr. Deepak Bhatt reviews trials evaluating the cardiovascular safety of new diabetes drugs such as DPP4 and GLP1 agonists.

Diabetes, glycemic control & vascular prevention

3' education - June 16, 2013 - CDMC Hanoi - Prof John Betteridge
##KEY_PHRASE##

Prof John Betteridge reviews the impact of various diabetic drugs on glycemic control, vascular prevention and Beta cell function.

HPS2-THRIVE and the future of clinical endpoint trials

3' education - May 12, 2013 - CDMC hanoi - Prof D John Betteridge
##KEY_PHRASE##

Prof.John Betteridge with a critical appraisal of the results of the HPS2-THRIVE trial and the relevance for clinical practice and design of future outcome trials

CV disease & diabetes in Asia

Hanoi, April 20 2013

10' education - Apr. 15, 2013

Effects of GLP-1 Analogs on Cardiovascular Health

3' education - Jan. 10, 2013 - LA, AHA 2012 - Dr. Richard Shannon
##KEY_PHRASE##

Dr. Richard Shannon, Pennsylvania,  recognizes that Diabetes is a CVD equivalent and focuses on the importance that incretins can play in improving hemodynamics and outcomes in Heart Failure.

Dual PPAR agonists in CV risk & diabetes

3' education - Dec. 11, 2012
##KEY_PHRASE##

Dr Michael Lincoff, Cleveland Clinic, about the potential for dual PPAR agonists in targeting excess CV risk in diabetes

Achieving optimal glycemic control: What are the current options in management?

3' education - Dec. 7, 2011
##KEY_PHRASE##

Prof. Bernard Charbonell (University of Nantes, France) discussed new options in diabetes management.

Diabetes & CV Risk: routine practice versus guidelines

3' education - July 29, 2011
##KEY_PHRASE##

Prof. E. Standl, Munich discusses the use of practice surveys to guideline recommendations to assess the potential for improvement in real-life.

Priorities in the management of type 2 diabetes

3' education - July 29, 2011
##KEY_PHRASE##

In this expert interview Professor Sir Alberti discusses why the epidemic rise in T2DM persists despite the availability of medicines.

Management of diabetes

3' education - July 26, 2011
##KEY_PHRASE##

as a cardiovascular disease Prof John Betteridge, London, discusses the evolution of diabetes therapy, the epidemic rise in diabetes, current and emerging diabetes therapies.

HbA1c: targets & recommendations

3' education - July 25, 2011
##KEY_PHRASE##

In this expert opinion prof. Guntram Schernthaner discusses the optimal target value of HbA1c, in diabetes or if combined with cardiovascular disease or renal impairment.

Optimal blood pressure management

3' education - July 22, 2011
##KEY_PHRASE##

Prof. Gordon McInnes , Glasgow, is discussing the optimal approach and targets for blood pressure reduction  in CV risk and diabetes

Diabetes & vascular risk:

3' education - June 16, 2011
##KEY_PHRASE##

Opportunities for lipid management, Ronald Ma, MD, The Chinese University of Hong Kong, in discussion with prof John Deanfield

TZD's and CV risk-benefit

3' education - Apr. 7, 2011
##KEY_PHRASE##

**Prof Mark Kearney, cardiogist, University of Leeds, UK, in discussion with Prof John Betteridge** the current opinions and perspectives on the use of TZD’s in type 2 diabetes & CV Risk.  

TZD's and CV risk-benefit

3' education - Apr. 7, 2011
##KEY_PHRASE##

**Dr Stephen Lawrence GP, St Mary's Island, CHATHAM KENT, UK, in discussion with Prof John Betteridge** the current opinions and perspectives on the use of TZD’s in type 2 diabetes & CV Risk.

TZD's and CV risk-benefit

3' education - Apr. 7, 2011
##KEY_PHRASE##

Dr John Reckless , Consultant Endocrinologist, University of Bath, UK, in discussion with Prof John Betteridge the current opinions and perspectives on the use of TZD’s in type 2 diabetes & CV Risk.

Diabetes & CV disease

3' education - Oct. 3, 2009
##KEY_PHRASE##

**in Asia; Do they need a different approach in management? **Prof. John Betteridge UCL, London United Kingdom

CV risk in diabetes

3' education - Sep. 28, 2009
##KEY_PHRASE##

**Asia: The Management of CV risk in diabetes and the metabolic syndrome **Dr David Waters San Francisco General Hospital, California, USA, June 2009, VBG Asia

Intervening in CV Risk

3' education - July 29, 2009
##KEY_PHRASE##

**Exploring New Insights in Diabetes & Cardiovascular disease **Prof John Deanfield & Prof John Betteridge University College London Directors PACE foundation

Glycemic control

3' education - July 29, 2009
##KEY_PHRASE##

**Sustained Glycemic control in (Pre) diabetes What and how is te best time to act? **Prof. Bernard Charbonnel University of Nantes, France

Hypertension and diabetes

3' education - July 29, 2009
##KEY_PHRASE##

**Managing hypertension to protect the diabetic patient: When and how to intervene? **Prof. Tom MacDonald University of Dundee, United Kingdom

Opportunities for ARB’s

3' education - July 29, 2009
##KEY_PHRASE##

**New opportunities for ARBs: Interventions in the course of CV risk & diabetes **Prof. Gordon McInnes, the The Western Infirmary, Glasgow, United Kingdom

Compliance in diabetes

3' education - July 29, 2009
##KEY_PHRASE##

**Are fixed dose therapies the solution to optimal care? **Prof Guntram Schernthaner, Rudolfstiftung Hospital, Vienna, Austria